Top Tweets for #gi25
🎙️🩺 Stephen Lam Chan, MBBS, MD, FRCP, of @CUHKofficial discusses data at #GI25 showing no benefit with adjuvant pembrolizumab in HCC after a complete radiologic response. 📉 #ASCO #oncology
Watch the full video here! https://t.co/z75tbWGWli
Perfect timing for publication as we approach @ASCO #GI26! Really blessed to have been able to meet and work with members of the @TheGutOncLab, many of which I met at #GI23 #GI24 #GI25. Conferences and networking help accelerate research!
More to come!
#MedTwitter #OncTwitter
On the heels of #GI26, happy to share this tour de force led by @SuriyaBaskarMD- “Precision Oncology Promise in the Management of Pancreatic Acinar Cell Carcinoma” in #EJC
➡️ PACC is rare (<2% of pancreatic cancers) and biologically distinct from PDAC. Emerging data show real promise for precision oncology- PARP inhibitors, ICIs, and targeted therapies in genomically selected cases.
🧬 Broad molecular & germline testing should be standard to improve outcomes in this underserved disease. @TheGutOncLab @TimothyJBrownMD @GIMedOnc @Deebacca @sawyer_bawek @BRoseMDMPH
ASCO GI is coming! Not exhaustive, not a ranking. Just a quick snapshot of orals and posters I’m circling as I walk the halls. A mix of practice-shaping data and signals of where the field is heading 👇
🟦 Ab 283. CRITICS-II. Neoadjuvant chemo vs chemo + RT vs RT alone in resectable gastric cancer.
Pairs nicely with ESOPEC. ESOPEC showed perioperative FLOT beat preop chemoradiation (CROSS). CRITICS-II shows adding radiation to perioperative chemo adds no survival benefit. Together, these trials likely suggest a shrinking role for radiation and reinforce perioperative chemo, especially FLOT, as the backbone.
🟦 Ab LBA284. ILUSTRO. Zolbetuximab + mFOLFOX6 + nivolumab in CLDN18.2+ gastric/GEJ cancer.
CLDN18.2 is real, but zolbetuximab toxicity remains an issue. GLOW paired it with CAPEOX and no IO; this adds immunotherapy. Key question is whether efficacy can outpace tolerability or whether we need better ways to hit this target.
🟦 HERIZONGEA-01. Zanidatamab + chemo ± tislelizumab in 1L HER2+ GEA.
Bring on the bispecifics 🔥 After years of incremental HER2 gains, dual-epitope targeting feels like the first real step forward. Can this finally move the needle meaningfully in 1L?
🟦 Ab 18. GLP-1 receptor agonist vs aspirin for primary CRC prevention.
Ooo. GLP-1 vs aspirin 👀 We keep hearing GLP-1s cause cancer. This asks the opposite question using real-world data. Metabolism, inflammation, and CRC risk colliding in an interesting way.
🟦 Ab 20. Liver transplantation for unresectable CRLM. Belgian real-world data.
TRANSMET changed the game. Now the question is durability and scalability outside trials. Selection, recurrence patterns, and real-world outcomes matter more than ever.
🟦 Ab 14. COMMIT. Atezo vs mFOLFOX/bev/atezo in 1L MSI-H metastatic CRC.
CHECKMATE-8HW suggested dual IO beats single-agent. More randomized data nudging us away from chemo for MSI-H disease is welcome, especially for patients who may never need it.
🟦 Ab TPS265. Telisotuzumab adizutecan vs SOC in post-adjuvant ctDNA+ CRC.
Phase III on deck. ctDNA-defined MRD is clearly the next battleground. The key question is how big the benefit needs to be to change adjuvant practice.
🟦 Ab TPS266. EpCAM × 4-1BB bsAb + PD-L1 × VEGF bsAb + chemo in mCRC.
The bispecifics are multiplying 😅 Two bispecifics. Four targets. One trial. Ambitious, complex, and very on-trend for MSS CRC immunotherapy.
🟦 Ab TPS275. TROP2 CAR IL-15–engineered cord blood NK cells + cetuximab in CRC MRD.
MRD studies everywhere, but adding cellular therapy makes this one stand out. If immune escalation is going to work, minimal disease is the place to try it.
🟦 Ab TPS273. BXQ-350 + mFOLFOX7/bev in 1L metastatic CRC.
First-line phase 1 with a new mechanism targeting sphingolipid metabolism. Early, but exactly the kind of biology-driven swing worth watching.
🟦 Ab 297. Peritoneal metastasis as an exclusion criterion in GI cancer trials.
Gut Onc Lab work 🙌 Shows how eligibility criteria have tightened over time, often excluding patients with peritoneal disease. Big implications for generalizability and equity. Fun writing the code for this effort.
That’s the start of my early ASCO GI hit list. I’ll inevitably miss something great. If there’s an abstract I should see, let me know in the comments or stop me in the hallway 👋
#GI26
@OncoAlert
@TheGutOncLab
3. BREAKWATER
✅Significant improvement in OS, PFS, and ORR with ENCO + CET + FOLFOX for BRAF V600E mut mCRC
👉Practice-changing!🎉
#GI25 #ASCO25 #ESMO25 @OncoAlert @NatureMedicine @NEJM @skopetz
2. CheckMate 8HW
✅Significant PFS improvement with Nivo + Ipi (vs Nivo) for MSI-H/dMMR mCRC (HR 0.62, p = 0.0003)
👉Practice-changing!🎉
#GI25 #ASCO25 #ESMO25 @OncoAlert @TheLancet
Year-End Poll!📊
Vote for the most impressive results in 2025! (CRC)
@OncoAlert #MedTwitter #OncoPoll #ASCO25 #ESMO25 #GI25
ctDNA analysis in the CALGB/SWOG 80702 @JAMAOnc (presented at #GI25)
✅CALGB/SWOG 80702: Adjuvant FOLFOX ± celecoxib for stage III colon cancer
✅Adding celecoxib improved DFS & OS in ctDNA+patients, irrespective of PIK3CA mutational status (no benefit in ctDNA-)
👉Does ctDNA supersede PIK3CA status as a biomarker? Validation warranted.
https://t.co/432aQSDxrO
@OncoAlert
➡️In GEJ cancer, local recurrence is less the problem → metastases drive mortality.
🎥@YJanjigianMD (@MSKCancerCenter): shift toward systemic periop therapy, thorough staging, & longer treatment to improve cures
🔗 https://t.co/rUSOTP0UGW
@myESMO #GI25 #STCsm #UroOnc #UroSoMe #ImmunoOnc #CTSM #TrialUpdate
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.
🎥Stephen Lam Chan (@CUHKofficial) discusses advances in targeted therapies for liver cancer:
🧬 TIM3/TIGIT immunotherapy
🧬 IL27-targeting cytokines
🧬 FGFR4 inhibitor+atezolizumab combo efficacy
Precision medicine rapidly advancing.
➡️ https://t.co/6npb4xXS6P
@myESMO #GI25 #HPBCsm #UroOnc #UroSoMe #ImmunoOnc
This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Takeda. Supporters have no influence over the production of content.
Plan your 2025 conference schedule better with @Larvol. Here is our list of the Top 25 Oncology Conferences worldwide.
Follow us for the latest updates: https://t.co/bW8jRb3bvS
#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI25 #GU25 #ASCO25 #EHA25 #AACR25 #ESMO25 #SITC25 #ASH25 #SABCS25 #2025Events #MedicalConferences
The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO
| @sitcancer | @IASLC | @SocietyofHemOnc | @AACR
@NiuSanford @ZhiVenFongMD @GIMedOnc @TheNotoriousHPB @ASCO @HalletJulie @SyedAAhmad5 @BasGrootKoerkam @MarcBesselink @OncoThor @ziadtawad @EileenMOReilly @cureGBC And #ACCELERATE 🏎️ 🇮🇳 presented at #GI25
https://t.co/6QvSZoYyIx
Multiple RAS(ON) inhibitors in the development pipeline are showing promise, some of which were presented at #GI25, including zoldonrasib and daraxonrasib in advanced solid tumors, including #PDAC. @AlexSpiraMDPhD #pancsm
https://t.co/KFtoMm10Fc
🚨 MATTERHORN Trial – ASCO 2025 Spotlight 🚨
Can perioperative immunotherapy change outcomes in resectable gastric/GEJ cancer?
At #GI25, MATTERHORN (Durvalumab + FLOT) showed:
pCR: 19% vs 7%
T0: 23% vs 11%
N0: 52% vs 36%
As Per press release: EFS is statistically significant and clinically meaningful.
But KN585 - PCR BENIFIT but no EFS gain
Why MATTERHORN may succeed where KEYNOTE-585 fell short:
100% got triplet chemo (vs 20% in KN585)
60% completed peri-op FLOT (vs 48 % )
Now your turn- put your brain 🧠 and give me your best guess for the EFS outcome?
HR and Gain in median EFS
See the POLL and Vote 🗳 👇
#ASCO25 #MATTERHORN @ASCO
@NiuSanford
@KrishanJethwa @GIMedOnc @dr_yakupergun @OncoAlert
Plan your 2025 conference schedule better with LARVOL. Here is our list of the Top 25 Oncology Conferences worldwide. Follow us for the latest updates!
#LARVOL #Oncology #CancerResearch #CancerData #CancerCare #OncologyUpdates #OncologyConferences #OncologyInsights #GI25 #GU25 #ASCO25 #EHA25 #AACR25 #ESMO25 #SITC25 #ASH25 #SABCS25 #2025Events #MedicalConferences
The conferences: @ASCO | @ASH_hematology | @SABCSSanAntonio | @EHA_Hematology | @myESMO | @sitcancer | @IASLC | @SocietyofHemOnc |@AACR
Drs. Heinz-Josef Lenz, Sara Lonardi, and John Strickler explore the latest data on #immunotherapy and #targetedtherapy options for #CRC, including recent data from #GI25. Watch today to expand your knowledge!
@PeerView https://t.co/kIcWH6WTkR
Low-dose aspirin to reduce recurrence rate in colorectal cancer Pts w/ PI3K pathway alterations: 3-yr results from a RCT [Jan 27, 2025] @Annamartling et al. ALASCCA Trial Study Group @ASCO #GI25 LBA125
https://t.co/jj2ELLInKq #crcsm PI3K #caprev #PrecisionMedicine #NCT02647099
![mtmdphd's tweet photo. Low-dose aspirin to reduce recurrence rate in colorectal cancer Pts w/ PI3K pathway alterations: 3-yr results from a RCT [Jan 27, 2025] @Annamartling et al. ALASCCA Trial Study Group @ASCO #GI25 LBA125
https://t.co/jj2ELLInKq #crcsm PI3K #caprev #PrecisionMedicine #NCT02647099 https://t.co/FdAm7EhnoS](https://pbs.twimg.com/media/GogJxZxXMAAdRWW.png)
@GIMedOnc This #gi25 study has limitations (as @SuyogCancer points out). Also, most stage 1-3 CRC pts don't have/need comp somatic testing.
I included ASA in my survivorship counseling along w exercise/red meat/alcohol/fiber after 👇🏼 NHS paper came out.
(https://t.co/YYX38fW73I)
With the use of gene expression profiling, there is evidence of an association between CLDN18 and MUC1 genes in #GastrointestinalCancers, according to Dr Aditya Shreenivas (@AdityaSunavs) of @cityofhope. @ASCO #GI25
Read the full Q&A:
https://t.co/yZb8iQm3CP
Yes, there will be multible streaming possibilities and co-streams this Goas Invitational.
The games can be watched in the official stream in the Tournament Discord (dm for invite), or live twitch streams from the participants perspective.🫡
#GoasInvitational #GI25 @GoasEzport
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.8M followers
Taylor Swift
@taylorswift13
82.7M followers
Lady Gaga
@ladygaga
74.2M followers
Virat Kohli
@imvkohli
71.6M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers